World Health Organization Raises Warning Over Severe Lack of Weight-Loss Injections
Fewer than one in 10 patients eligible to benefit from weight-loss injections including Wegovy have access to them, states the global health agency as it releases its first recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our new guidelines affirms that excess weight is a long-term condition that can be managed with thorough and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are significant barriers to broad access to the jabs that can assist patients in reducing substantial weight, explains the body.
Skinny Jab Shortage
Even in the present most favorable outlook, the supply of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of those who need them, as stated by the health organization.
The recommendation urges countries and companies to increase availability, via strategies such as patent sharing.
A patent on a key compound – the main component of a leading brand – is scheduled to end in several countries in 2026.
How Obesity Jabs Work
These medications mimick a biological compound to reduce digestion speed, curb appetite and enhance satiety so people eat less.
People usually begin shedding pounds in the initial weeks of commencing the weekly injections.
Research points to people may see weight return a year later of halting the medication, because their normal food cravings come back.
Being overweight or obese elevates your risk for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight affects individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.
